Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	SEP 22	MATHDI to be removed from STN

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:18:35 ON 27 SEP 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:18:43 ON 27 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2005 HIGHEST RN 863963-04-6
DICTIONARY FILE UPDATES: 26 SEP 2005 HIGHEST RN 863963-04-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Documents and Settings\VBalasubramania\My Documents\STNEXP4\QUERIES\10618868.str



chain nodes :
19 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
2-25 6-24 13-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18

exact/norm bonds :
2-25 6-24 13-19
exact bonds :
7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 : 13 :

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
24:CLASS 25:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR





G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:19:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 403 TO ITERATE

100.0% PROCESSED 403 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6856 TO 9264
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> d scan

L2 5 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Pyrimidinemethanol, 4-[(3S,5R)-3,5-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)- (9CI)
MF C21 H32 N8 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L2 5 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazinone, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-propyl- (9CI)
MF C27 H28 Cl F4 N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4-Pyrimidinamine, 2,6-bis(4-methyl-1-piperazinyl)- (9CI)
MF C14 H25 N7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4-Pyrimidinamine, 2-(4-methyl-1-piperazinyl)-5-nitro-6-[4-(phenylmethyl)-1-piperazinyl]- (9CI)
MF C20 H28 N8 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrimidine, 5-[(p-chlorophenyl)thio]-2,4-bis(4-methyl-1-piperazinyl)-
(6CI, 7CI)
MF C20 H27 Cl N6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 14:19:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7950 TO ITERATE

100.0% PROCESSED 7950 ITERATIONS 132 ANSWERS
SEARCH TIME: 00.00.01

L3 132 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.76	161.97

FILE 'CAPLUS' ENTERED AT 14:19:39 ON 27 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Sep 2005 VOL 143 ISS 14
FILE LAST UPDATED: 26 Sep 2005 (20050926/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 30 L3

=> d l4 1-39 bib hitstr

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:71173 CAPLUS
DN 142:176866
TI Preparation of biaryl piperazinyl-pyridine analogues as capsaicin receptor modulators
IN Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Chenard, Bertrand L.; De Lombaert, Stephane; Hodgetts, Kevin J.; Hutchison, Alan; Yoon, Taeyoung; Zheng, Xiaozhang
PA Neurogen Corporation, USA
SO PCT Int. Appl., 381 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005007648	A2	20050127	WO 2004-US23064	20040716
	WO 2005007648	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-488564P P 20030716
US 2003-516135P P 20031031
OS MARPAT 142:176866
IT **833468-13-6P 833468-14-7P 833468-27-2P**
833468-38-5P 833468-63-6P 833468-79-4P
833468-88-5P 833468-89-6P 833468-90-9P
833468-91-0P 833468-92-1P 833468-93-2P
833468-94-3P 833468-95-4P 833468-99-8P
833469-06-0P 833469-08-2P 833469-10-6P
833469-17-3P 833469-22-0P 833469-28-6P
833469-32-2P 833469-38-8P 833469-47-9P
833469-53-7P 833469-81-1P 833470-14-7P
833470-43-2P 833470-51-2P 833470-52-3P
833470-82-9P 833471-00-4P 833471-50-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor modulators)

RN 833468-13-6 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-14-7 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(4-propyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-27-2 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(4-piperidinyloxy)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-38-5 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[4-(methylsulfonyl)-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-63-6 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[4-(1-methylethyl)-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-79-4 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(3-methyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-88-5 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(4-ethyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-89-6 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[4-(cyclopropylmethyl)-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-90-9 CAPLUS
CN Piperazine, 1-acetyl-4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833468-91-0 CAPLUS
CN Piperazine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 833468-92-1 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833468-93-2 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-[(2S,5R)-2,4,5-trimethyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833468-94-3 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2-methyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-95-4 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(2,4-dimethyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833468-99-8 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2-(3,4-dimethyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-06-0 CAPLUS
CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(3-methyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-08-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-(4-fluoro-3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 833469-10-6 CAPLUS
CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-17-3 CAPLUS
CN 1-Piperazineacetamide, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 833469-22-0 CAPLUS
CN Piperazine, 1-[4-(4-fluoro-3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-(1-iminoethyl)- (9CI) (CA INDEX NAME)



RN 833469-28-6 CAPLUS
CN Piperazine, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-(1-iminoethyl)- (9CI) (CA INDEX NAME)



RN 833469-32-2 CAPLUS
CN Pyrimidine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluoro-3-methylphenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-38-8 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-2,6-bis[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-47-9 CAPLUS
CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-(4-propyl-1-piperazinyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-53-7 CAPLUS
CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-[4-(methylsulfonyl)-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833469-81-1 CAPLUS
CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-2-[4-(1-methylethyl)-1-piperazinyl]-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 833470-14-7 CAPLUS
CN 1-Piperazineethanol, 4-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833470-43-2 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833470-51-2 CAPLUS
CN Pyrimidine, 4-(4-fluoro-3-methylphenyl)-6-[(2R)-2-methyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833470-52-3 CAPLUS
CN Pyrimidine, 4-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-6-(3,4-difluorophenyl)-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833470-82-9 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3,5-dimethyl-2-pyridinyl)-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 833471-00-4 CAPLUS
CN Pyrimidine, 4-(5-chloro-3-pyridinyl)-6-[(2R)-4-(3-chloro-2-pyridinyl)-2-methyl-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 833471-50-4 CAPLUS
CN Pyrimidine, 4-(3-chloro-4-fluorophenyl)-6-[4-(3-methyl-2-pyridinyl)-1-piperazinyl]-2-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



IT **833471-45-7 833471-46-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor modulators)

RN 833471-45-7 CAPLUS

CN Piperazinone, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 833471-46-8 CAPLUS

CN Piperazinone, 1-[4-(3-chloro-4-fluorophenyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-2-pyrimidinyl]-4-propyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:718534 CAPLUS

DN 141:243344

TI Preparation of 1-[(3-pyridinyl)carbonyl]pyrrolidine derivatives as immunosuppressants

IN Baxter, Andrew; Eyssade, Christine; Guile, Simon; King, Sarah; Pimm, Austen; Reuberson, James; Thorne, Philip

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004074278	A1	20040902	WO 2004-SE216	20040218

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,

BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI SE 2003-456 A 20030219

OS MARPAT 141:243344

IT **749897-98-1P 749899-46-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-[(3-pyridinyl)carbonyl]pyrrolidine derivs. as immunosuppressants)

RN 749897-98-1 CAPLUS

CN Pyrrolidine, 1-[[6-[4-[[4-(4-methyl-1-piperazinyl)-2-pyrimidinyl]oxy]-1-piperidinyl]-3-pyridinyl]carbonyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)



RN 749899-46-5 CAPLUS

CN Pyrrolidine, 1-[[6-[4-[[4-(4-methyl-1-piperazinyl)-2-pyrimidinyl]oxy]-1-piperidinyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:589378 CAPLUS
DN 141:134074
TI Thiosemicarbazones as anti-virals and immunopotentiators
IN Barsanti, Paul; Brammeier, Nathan; Diebes, Anthony; Lagniton, Liana; Ng, Simon; Ni, Zhi-Jie; Pfister, Keith B.; Philbin, Casey; Valiante, Nicholas; Wagman, Allan; Wang, Weibo; Weiner, Amy
PA Chiron Corporation, USA
SO PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004060308	A2	20040722	WO 2003-US41493	20031229
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005069555	A1	20050331	US 2003-748071	20031229
PRAI	US 2002-436472P	P	20021227		
	US 2002-436638P	P	20021230		
	US 2003-438987P	P	20030110		

IT **725727-11-7P 725727-23-1P 725727-24-2P**
725727-25-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(thiosemicarbazones as antivirals and immunostimulants)

RN 725727-11-7 CAPLUS

CN Hydrazinecarbothioamide, 2-[[4-(4-methyl-1-piperazinyl)-2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-5-pyrimidinyl]methylene]- (9CI) (CA INDEX NAME)



RN 725727-23-1 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-4-(4-methyl-1-piperazinyl)-5-pyrimidinyl]methylene]- (9CI) (CA INDEX NAME)



RN 725727-24-2 CAPLUS

CN Hydrazinecarbothioamide, 2-[[4-(4-methyl-1-piperazinyl)-2-[4-(phenylmethyl)-1-piperazinyl]-5-pyrimidinyl]methylene]- (9CI) (CA INDEX NAME)



RN 725727-25-3 CAPLUS

CN Hydrazinecarbothioamide, 2-[[2-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]-4-[4-(1-methylethyl)-1-piperazinyl]-5-pyrimidinyl]methylene]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:354725 CAPLUS
DN 140:357371
TI Preparation of 2,4,6-triaminopyrimidines as GalR3 antagonists for the treatment of depression and/or anxiety
IN Packiarajan, Mathivanan
PA Synaptic Pharmaceutical Corporation, USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004034967	A2	20040429	WO 2003-US25134	20030807
	WO 2004034967	A3	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-215258 A 20020807
IT **681836-69-1P**, N-(3,4-Dichlorophenyl)-2,6-bis[4-(2-pyridinyl)-1-piperazinyl]-4-pyrimidinamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2,4,6-triaminopyrimidines as GalR3 antagonists for treatment of depression and/or anxiety)
RN 681836-69-1 CAPLUS
CN 4-Pyrimidinamine, N-(3,4-dichlorophenyl)-2,6-bis[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:354683 CAPLUS
DN 140:375187
TI Preparation of 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
IN Packiarajan, Mathivanan
PA H. Lunobeck A/S, USA
SO U.S. Pat. Appl. Publ., 39 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004082587	A1	20040429	US 2003-638602	20030807
	US 6936607	B2	20050830		
PRAI	US 2002-401939P	P	20020807		

IT **681836-69-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety)
RN 681836-69-1 CAPLUS
CN 4-Pyrimidinamine, N-(3,4-dichlorophenyl)-2,6-bis[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182866 CAPLUS
DN 140:236096
TI Preparation of proline derivatives as antibacterial agents
IN Fujita, Masahiro; Sakamoto, Masato; Horiuchi, Nobuhiko; Yamamoto, Takayoshi; Tomita, Kyoji; Mizuno, Kazuhiro; Niga, Toshiyuki; Ito, Hideaki; Kashimoto, Shigeki
PA Dainippon Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018453	A1	20040304	WO 2003-JP10548	20030821
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2002-242795	A	20020823		
	JP 2002-339200	A	20021122		
	JP 2003-27010	A	20030204		

OS MARPAT 140:236096
IT **668483-58-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of proline derivs. as antibacterial agents against multidrug-resistant bacteria)
RN 668483-58-7 CAPLUS
CN Piperazine, 1-[(2R)-N-formyl-N-hydroxy-2-pentyl-β-alanyl-L-prolyl]-4-[4-(4-methyl-1-piperazinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:737742 CAPLUS
DN 139:276884
TI Preparation of sulfonyl-derivatives as novel inhibitors of histone deacetylase
IN Van Emelen, Kristof; Arts, Janine; Backx, Leo Jacobus Jozef; De Winter, Hans Louis Jos; Van Brandt, Sven Franciscus Anna; Verdonck, Marc Gustaaf Celine; Meerpoel, Lieven; Pilatte, Isabelle Noeelle Constance; Poncelet, Virginie Sophie; Dyatkin, Alexey Borisovich
PA Janssen Pharmaceutica N.V., Belg.; et al.
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076422	A1	20030918	WO 2003-EP2516	20030311
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2476586	AA	20030918	CA 2003-2476586	20030311
	EP 1485365	A1	20041215	EP 2003-711982	20030311
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007575	A	20041221	BR 2003-7575	20030311
	US 2005113373	A1	20050526	US 2003-507708	20030311
	JP 2005525380	T2	20050825	JP 2003-574641	20030311
PRAI	US 2002-363799P	P	20020313		
	US 2002-420989P	P	20021024		
	WO 2003-EP2516	W	20030311		

OS MARPAT 139:276884
IT **604768-47-0P 604768-48-1P 604768-49-2P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of sulfonyl derivs. as histone deacetylase inhibitors and antitumor agent for treatment of cancer)
RN 604768-47-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2,4-bis[4-(2-naphthalenylsulfonyl)-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 604768-48-1 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2,4-bis[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 604768-49-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2,4-bis[4-(2-naphthalenylsulfonyl)-1-piperazinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **604769-15-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonyl derivs. as histone deacetylase inhibitors and antitumor agent for treatment of cancer)

RN 604769-15-5 CAPLUS
CN 5-Pyrimidinecarboxamide, N-hydroxy-2,4-bis[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:664429 CAPLUS
DN 137:332746
TI A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action: 1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)-2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol
AU Mylari, Banavara L.; Oates, Peter J.; Zembrowski, William J.; Beebe, David A.; Conn, Edward L.; Coutcher, James B.; O'Gorman, Melissa T.; Linhares, Michael C.; Withbroe, Gregory J.
CS Groton Laboratories, Pfizer Global Research and Development, Groton, CT, 06340, USA
SO Journal of Medicinal Chemistry (2002), 45(20), 4398-4401
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:332746
IT **300551-11-5P 474099-89-3P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure-activity relationship studies of sorbitol dehydrogenase inhibitors, dimethylpiperazinyl pyrimidine analogs)
RN 300551-11-5 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(2R,6S)-2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 474099-89-3 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(2R,6S)-2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **474100-19-1P 474100-25-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and structure-activity relationship studies of sorbitol dehydrogenase inhibitors, dimethylpiperazinyl pyrimidine analogs)

RN 474100-19-1 CAPLUS
CN Pyrimidine, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-(4-methyl-1-piperazinyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 474100-25-9 CAPLUS
CN Pyrimidine, 2-[(1R)-1-butoxyethyl]-4-[(2R,6S)-2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:428741 CAPLUS

DN 137:10996
TI Combination of GABA agonists and sorbitol dehydrogenase inhibitors
IN Mylari, Banavara Lakshman
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002043762	A2	20020606	WO 2001-IB2213	20011119
	WO 2002043762	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2430298	AA	20020606	CA 2001-2430298	20011119
	AU 2002015159	A5	20020611	AU 2002-15159	20011119
	EP 1337271	A2	20030827	EP 2001-983739	20011119
	EP 1337271	B1	20041103		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001015783	A	20030916	BR 2001-15783	20011119
	EE 200300248	A	20031015	EE 2003-248	20011119
	JP 2004514699	T2	20040520	JP 2002-545732	20011119
	AT 281181	E	20041115	AT 2001-983739	20011119
	PT 1337271	T	20050131	PT 2001-983739	20011119
	ES 2230378	T3	20050501	ES 2001-1983739	20011119
	US 2002091128	A1	20020711	US 2001-997038	20011129
	US 6544998	B2	20030408		
	ZA 2003003381	A	20040430	ZA 2003-3381	20030430
	BG 107774	A	20040130	BG 2003-107774	20030507
	NO 2003002441	A	20030703	NO 2003-2441	20030528
PRAI	US 2000-250069P	P	20001130		
	WO 2001-IB2213	W	20011119		

OS MARPAT 137:10996
IT **300551-11-5 300551-17-1 300551-19-3**
300551-20-6 300552-03-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of GABA agonists and sorbitol dehydrogenase inhibitors)
RN 300551-11-5 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(2R,6S)-2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 300551-17-1 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3S,5R)-3,5-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-19-3 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3R,5S)-4-[2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-3,5-dimethyl-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-20-6 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3R,5S)-3,5-dimethyl-4-[2-[4-(1-methylethyl)-1-piperazinyl]-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300552-03-8 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(2R,6S)-4-[2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-2,6-dimethyl-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:314757 CAPLUS
DN 136:345787
TI Combination of statins and sorbitol dehydrogenase inhibitors
IN Mylari, Banavara Lakshman
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032411	A2	20020425	WO 2001-IB1506	20010820
	WO 2002032411	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2426592	AA	20020425	CA 2001-2426592	20010820
	AU 2001076645	A5	20020429	AU 2001-76645	20010820
	EP 1326591	A2	20030716	EP 2001-954305	20010820
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004517053	T2	20040610	JP 2002-535649	20010820
	US 2003186994	A1	20031002	US 2001-974414	20011009
	ZA 2003002229	A	20040505	ZA 2003-2229	20040320
PRAI	US 2000-241339P	P	20001018		

WO 2001-IB1506 W 20010820

IT **300551-11-5 300551-17-1 300551-19-3**
300551-20-6 300552-03-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of statins and sorbitol dehydrogenase inhibitors)

RN 300551-11-5 CAPLUS

CN 2-Pyrimidinemethanol, 4-[(2R,6S)-2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 300551-17-1 CAPLUS

CN 2-Pyrimidinemethanol, 4-[(3S,5R)-3,5-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-19-3 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3R,5S)-4-[2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-3,5-dimethyl-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-20-6 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3R,5S)-3,5-dimethyl-4-[2-[4-(1-methylethyl)-1-piperazinyl]-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300552-03-8 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(2R,6S)-4-[2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-2,6-dimethyl-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:936092 CAPLUS
DN 136:53752

TI Synthesis and use of mono-, di- and triethanolamine salts of zopolrestat alone and in combination with (e.g.) NHE-1 inhibitors
IN Mylari, Banavara L.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001056095	A1	20011227	US 2001-782798	20010213
	US 6570013	B2	20030527		
	WO 2002098429	A1	20021212	WO 2001-IB1031	20010607
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003212072	A1	20031113	US 2003-404628	20030401
PRAI	US 2000-183004P	P	20000216		
	US 2001-782798	A	20010213		

IT **300551-11-5**, 1R-[4-[2R,6S-Dimethyl-4-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyrimidin-2-yl]ethanol
300551-17-1, 1R-[4-[3R,5S-Dimethyl-4-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]piperazin-1-yl]pyrimidin-2-yl]ethanol
300551-19-3, 1R-[4-[4-[2-(4-Ethylpiperazin-1-yl)pyrimidin-4-yl]-3R,5S-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol **300551-20-6**, 1R-[4-[4-[2-(4-Isopropylpiperazin-1-yl)pyrimidin-4-yl]-3R,5S-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol **300552-03-8**, 1R-[4-[4-[2-(4-Ethylpiperazin-1-yl)pyrimidin-4-yl]-2R,6S-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; synthesis and use of mono-, di- and triethanolamine salts of zopolrestat alone and in combination with (e.g.) NHE-1 inhibitors)

RN 300551-11-5 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(2R,6S)-2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 300551-17-1 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3S,5R)-3,5-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-19-3 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3R,5S)-4-[2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-3,5-dimethyl-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-20-6 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3R,5S)-3,5-dimethyl-4-[2-[4-(1-methylethyl)-1-piperazinyl]-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300552-03-8 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(2R,6S)-4-[2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-2,6-dimethyl-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:725471 CAPLUS
DN 133:281794
TI Preparation of aminopyrimidines as sorbitol dehydrogenase inhibitors
IN Chu-moyer, Margaret Yuhua; Murry, Jerry Anthony; Mylari, Banavara Lakshman; Zembrowski, William James
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 328 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059510	A1	20001012	WO 2000-IB296	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2366858	AA	20001012	CA 2000-2366858	20000316
CA 2484282	AA	20001012	CA 2000-2484282	20000316
AU 2000031845	A5	20001023	AU 2000-31845	20000316
AU 768720	B2	20040108		
NZ 514144	A	20010928	NZ 2000-514144	20000316
BR 2000009433	A	20020115	BR 2000-9433	20000316
TR 200102810	T2	20020121	TR 2001-200102810	20000316
EP 1185275	A1	20020313	EP 2000-909565	20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO				
	JP 2002541109	T2	20021203	JP 2000-609073	20000316
	JP 3581103	B2	20041027		
	EE 200100509	A	20021216	EE 2001-509	20000316
	US 6414149	B1	20020702	US 2000-538039	20000329
	NO 2001004642	A	20011128	NO 2001-4642	20010925
	HR 2001000716	A1	20021231	HR 2001-716	20011001
	ZA 2001008039	A	20030722	ZA 2001-8039	20011001
	BG 106038	A	20020628	BG 2001-106038	20011023
	US 2003065179	A1	20030403	US 2002-87869	20020228
	US 6602875	B2	20030805		
	US 6660740	B1	20031209	US 2003-384424	20030310
	US 2004077671	A1	20040422	US 2003-645401	20030821
	US 6869943	B2	20050322		
	US 2005020578	A1	20050127	US 2004-918812	20040812
	US 6936600	B2	20050830		
PRAI	US 1999-127437P	P	19990401		
	CA 2000-2366858	A3	20000316		
	WO 2000-IB296	W	20000316		
	US 2000-538039	A3	20000329		
	US 2002-87869	A3	20020228		
	US 2003-384424	A3	20030310		
	US 2003-645401	A3	20030821		

OS MARPAT 133:281794

IT **300551-09-1P 300551-11-5P 300551-17-1P**
300551-19-3P 300551-20-6P 300552-03-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyrimidines as sorbitol dehydrogenase inhibitors)

RN 300551-09-1 CAPLUS

CN 2-Pyrimidinemethanol, 4-[(3R,5S)-3,5-dimethyl-4-[4-(4-methyl-1-piperazinyl)-2-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-11-5 CAPLUS

CN 2-Pyrimidinemethanol, 4-[(2R,6S)-2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 300551-17-1 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3S,5R)-3,5-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-19-3 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3R,5S)-4-[2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-3,5-dimethyl-1-piperazinyl]-α-methyl-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300551-20-6 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(3R,5S)-3,5-dimethyl-4-[2-[4-(1-methylethyl)-1-piperazinyl]-4-pyrimidinyl]-1-piperazinyl]-α-methyl-, (αR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300552-03-8 CAPLUS
CN 2-Pyrimidinemethanol, 4-[(2R,6S)-4-[2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-2,6-dimethyl-1-piperazinyl]-α-methyl-, (αR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **300553-11-1P 300553-14-4P 300553-17-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminopyrimidines as sorbitol dehydrogenase inhibitors)
RN 300553-11-1 CAPLUS
CN Pyrimidine, 4-[(2R,6S)-2,6-dimethyl-4-(phenylmethyl)-1-piperazinyl]-2-(4-methyl-1-piperazinyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 300553-14-4 CAPLUS
CN Pyrimidine, 4-[(2R,6S)-2,6-dimethyl-1-piperazinyl]-2-(4-methyl-1-piperazinyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 300553-17-7 CAPLUS
CN Butanoic acid, (1R)-1-[4-[(3S,5R)-3,5-dimethyl-4-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-2-pyrimidinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:271340 CAPLUS
DN 130:296691
TI Preparation of substituted pyrimidines for the treatment of neurodegenerative or neurological disorders of the central nervous system
IN Kelley, James L.; Krenitsky, Thomas A.; Beauchamp, Lilia M.
PA Krenitsky Pharmaceuticals Inc., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9919305	A2	19990422	WO 1998-US21517	19981013
	WO 9919305	A3	19990624		
	W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2305255	AA	19990422	CA 1998-2305255	19981013
	AU 9896939	A1	19990503	AU 1998-96939	19981013
	EP 1025091	A1	20000809	EP 1998-951046	19981013
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001519416	T2	20011023	JP 2000-515878	19981013
	US 6440965	B1	20020827	US 2000-529559	20000414
PRAI	US 1997-62339P	P	19971015		
	WO 1998-US21517	W	19981013		

OS MARPAT 130:296691

IT **223435-21-0P 223435-38-9P 223435-39-0P 223435-40-3P 223435-41-4P 223435-79-8P 223435-95-8P 223436-11-1P 223436-14-4P 223436-16-6P 223436-18-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrimidines for the treatment of neurodegenerative or neurol. disorders of the central nervous system)

RN 223435-21-0 CAPLUS
CN Pyrimidine, 5-(4-chlorophenoxy)-2,4-bis(4-ethyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 223435-38-9 CAPLUS
CN 1-Piperazineethanol, 4-[5-(4-chlorophenoxy)-2-(4-phenyl-1-piperazinyl)-4-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 223435-39-0 CAPLUS
CN 1-Piperazineethanol, 4-[5-(4-chlorophenoxy)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 223435-40-3 CAPLUS
CN 1-Piperazineethanol, 4-[5-(4-chlorophenoxy)-2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 223435-41-4 CAPLUS
CN 1-Piperazineethanol, 4,4'-[5-(4-chlorophenoxy)-2,4-pyrimidinediyl]bis-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 223435-79-8 CAPLUS
CN Pyrimidine, 2,4-bis(4-methyl-1-piperazinyl)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 223435-95-8 CAPLUS
CN Pyrimidine, 5-(4-chlorophenoxy)-2,4-bis(4-ethyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 223436-11-1 CAPLUS
CN 1-Piperazineethanol, 4-[5-(4-chlorophenoxy)-2-(4-phenyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 223436-14-4 CAPLUS
CN 1-Piperazineethanol, 4-[5-(4-chlorophenoxy)-2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 223436-16-6 CAPLUS
CN 1-Piperazineethanol, 4-[5-(4-chlorophenoxy)-2-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 223436-18-8 CAPLUS
CN 1-Piperazineethanol, 4,4'-[5-(4-chlorophenoxy)-2,4-pyrimidinediyl]bis- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:42619 CAPLUS
DN 130:110283
TI Nucleobase heterocyclic combinatorialization
IN Cook, Phillip Dan; An, Haoyun; Guinosso, Charles J.; Fraser, Allister S.; Kawasaki, Andrew M.
PA Isis Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9900669	A1	19990107	WO 1998-US13666	19980630
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6893815	B1	20050517	US 1997-884873	19970630
	US 2002009748	A1	20020124	US 1998-76983	19980513
	AU 9881791	A1	19990119	AU 1998-81791	19980630
	US 2003003505	A1	20030102	US 2002-87424	20020301
PRAI	US 1997-884873	A2	19970630		
	US 1998-76983	A1	19980513		
	WO 1998-US13666	W	19980630		

IT **219688-51-4P 219688-61-6P 219688-66-1P 219688-72-9P 219688-84-3P 219688-88-7P 219688-92-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(combinatorialization of nucleobase heterocyclic)
RN 219688-51-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-(1-piperazinyl)-6-(1-piperazinylmethyl)-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 219688-61-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4,4'-(6-chloro-2,4-pyrimidinediyl)bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 219688-66-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4,4'-(6-hydrazino-2,4-pyrimidinediyl)bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 219688-72-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4,4'-(6-amino-2,4-pyrimidinediyl)bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 219688-84-3 CAPLUS
CN Pyrimidine, 4-chloro-2,6-bis[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 219688-88-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2,6-bis[4-(phenylmethyl)-1-piperazinyl]-, hydrazone (9CI) (CA INDEX NAME)



RN 219688-92-3 CAPLUS
CN 4-Pyrimidinamine, 2,6-bis[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



IT **219688-56-9P 219688-78-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(combinatorialization of nucleobase heterocyclic)
RN 219688-56-9 CAPLUS
CN Pyrimidine, 2,4-di-1-piperazinyl-6-(1-piperazinylmethyl)-, hexahydrochloride (9CI) (CA INDEX NAME)



● 6 HCl

RN 219688-78-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4,4'-[6-[2,6-dioxo-4-(phenylmethyl)-1-piperazinyl]-2,4-pyrimidinediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:266069 CAPLUS
DN 126:277444
TI Synthesis and properties of 2,4-disubstituted 6-fluoropyrimidines
AU Popova, L. M.; Studentsov, E. P.
CS St. Peterburg. Gos. Tekhnol. Inst., St. Petersburg, 198013, Russia
SO Zhurnal Organicheskoi Khimii (1996), 32(9), 1424-1428
CODEN: ZORKAE; ISSN: 0514-7492
PB Nauka
DT Journal
LA Russian
OS CASREACT 126:277444
IT **188987-74-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 188987-74-8 CAPLUS
CN Pyrimidine, 4-fluoro-2,6-di-1-piperazinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:877912 CAPLUS
DN 124:223
TI Structure-activity relationship studies of CNS agents. Part 25. 4,6-Di(heteroaryl)-2-(N-methylpiperazino)pyrimidines as new, potent 5-HT2A receptor ligands: a verification of the topographic model
AU Mokrosz, Maria J.; Strekowski, Lucjan; Kozak, Wei Xing; Duszynska, Beata; Bojarski, Andrzej J.; Klodzinska, Aleksandra; Czarny, Agnieszka; Cegla,

Marek T.; Deren-Wesolek, Anna; et al.
CS Department Medicinal Chemistry, Institute Pharmacology, Polish Academy Sciences, Krakow, 31-343, Pol.
SO Archiv der Pharmazie (Weinheim, Germany) (1995), 328(9), 659-66
CODEN: ARPMAS; ISSN: 0365-6233
PB VCH
DT Journal
LA English
IT **171115-23-4P**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(structure-activity relationship studies of di(heteroaryl)(N-methylpiperazino)pyrimidines as new and potent 5-HT2A receptor ligands and verification of topog. model)
RN 171115-23-4 CAPLUS
CN Pyrimidine, 4-(2-benzofuranyl)-2,6-bis(4-methyl-1-piperazinyl)-, dihydrochloride, monohydrate (9CI) (CA INDEX NAME)



●2 HCl

● H_2O

L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:534139 CAPLUS
DN 121:134139
TI Preparation of pharmaceutically active bicyclic-heterocyclic amines
IN Ayer, Donald E.; Bundy, Gordon L.; Jacobsen, Eric Jon
PA Upjohn Co., USA
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9320078	A1	19931014	WO 1993-US2188	19930316

W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG

	AU 9339174	A1	19931108	AU 1993-39174	19930316
	AU 675932	B2	19970227		
	EP 633886	A1	19950118	EP 1993-908303	19930316
	EP 633886	B1	20001018		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 70954	A2	19951128	HU 1994-2829	19930316
	JP 08502721	T2	19960326	JP 1993-517457	19930316
	RU 2103272	C1	19980127	RU 1994-42466	19930316
	PL 175347	B1	19981231	PL 1993-305430	19930316
	PL 175327	B1	19981231	PL 1993-317810	19930316
	AT 197051	E	20001115	AT 1993-908303	19930316
	ES 2150941	T3	20001216	ES 1993-908303	19930316
	PT 633886	T	20010330	PT 1993-908303	19930316
	NO 9403655	A	19941205	NO 1994-3655	19940930
	NO 303542	B1	19980727		
	FI 9404602	A	19941003	FI 1994-4602	19941003
	US 5502187	A	19960326	US 1994-317934	19941003
	GR 3035188	T3	20010430	GR 2001-400006	20010104
	LV 12794	B	20020620	LV 2001-150	20011018
PRAI	US 1992-863646	A2	19920403		
	WO 1993-US2188	A	19930316		
	US 1993-128957	B1	19930929		
	US 1994-222995	B1	19940405		

OS MARPAT 121:134139

IT **157014-22-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for pyrrolopyrimidine drug)

RN 157014-22-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4,4'-[6-(methylamino)-2,4-pyrimidinediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1990:478321 CAPLUS

DN 113:78321

TI Chemotherapeutic agents. XVI. Synthesis of pyrimidines and fused pyrimidines as leishmanicides

AU Ram, Vishnu J.

CS Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, 226 001, India

SO Journal fuer Praktische Chemie (Leipzig) (1989), 331(6), 957-63
CODEN: JPCEAO; ISSN: 0021-8383

DT Journal

LA English

OS CASREACT 113:78321

IT **128640-86-8P 128640-87-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 128640-86-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(3-methoxyphenyl)-2,6-bis(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 128640-87-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-(3-methoxyphenyl)-2,6-bis(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:478020 CAPLUS
DN 111:78020
TI Preparation of pharmaceutically active heterocyclic amines and their use for treating head injury, spinal trauma, stroke, etc.
IN McCall, John M.; Ayer, Donald E.; Jacobsen, E. Jon; Van Doornik, Frederick J.; Palmer, John R.
PA Upjohn Co., USA
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8808424	A1	19881103	WO 1988-US1212	19880420
	W: AU, DK, FI, JP, KR, NO, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	CA 1338012	A1	19960130	CA 1988-564335	19880415
	EP 293078	A1	19881130	EP 1988-303576	19880420
	R: ES, GR				
	AU 8817098	A1	19881202	AU 1988-17098	19880420
	AU 624788	B2	19920625		
	EP 358676	A1	19900321	EP 1988-904101	19880420
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				

	JP 02503198	T2	19901004	JP 1988-503777	19880420
	JP 07103118	B4	19951108		
	EP 487510	A1	19920527	EP 1992-200013	19880420
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5120843	A	19920609	US 1989-425726	19891023
	DK 8905335	A	19891026	DK 1989-5335	19891026
PRAI	US 1987-43274	A2	19870427		
	WO 1988-US1212	A	19880420		

OS MARPAT 111:78020

IT **111641-14-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of, as intermediate for pharmaceutically active heterocyclic amines)

RN 111641-14-6 CAPLUS

CN Pyrimidine, 2,4-bis(4-methyl-1-piperazinyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1988:631361 CAPLUS

DN 109:231361

TI Amino steroids useful for treating a variety of conditions, and a process for their preparation

IN McCall, John M.; Ayer, Donald E.; Jacobsen, E. Jon; Van Doorick, Frederick J.; Palmer, John R.; Karnes, Harold A.

PA Upjohn Co., USA

SO Eur. Pat. Appl., 90 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 263213	A1	19880413	EP 1986-307808	19861009
	EP 263213	B1	19950906		
	R: AT, ES, GR				
	ES 2078890	T3	19960101	ES 1986-307808	19861009
PRAI	EP 1986-307808	A	19861009		

OS CASREACT 109:231361; MARPAT 109:231361

IT **111640-52-9P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as drug)

RN 111640-52-9 CAPLUS

CN Pregna-4,9(11)-diene-3,20-dione, 21-[4-[2,6-bis(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-17-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **111641-14-6P 111669-14-8P,** 2,4-Bis(4-methylpiperazino)-6-chloropyrimidine
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for amino steroids)
RN 111641-14-6 CAPLUS
CN Pyrimidine, 2,4-bis(4-methyl-1-piperazinyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 111669-14-8 CAPLUS
CN Pyrimidine, 4-chloro-2,6-bis(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1988:6287 CAPLUS
DN 108:6287
TI Amino-substituted steroids having a variety of pharmacological activities, and processes for their preparation
IN McCall, John M.; Jacobsen, E. Jon; Van Doornik, Frederick J.; Palmer, John

R.; Karnes, Harold A.
PA Upjohn Co., USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8701706	A2	19870326	WO 1986-US1797	19860828
	WO 8701706	A3	19870716		
	W: AU, DK, FI, JP, KR, NO, SU, US, US, US, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	IL 79702	A1	19920216	IL 1986-79702	19860812
	IL 98007	A1	19920216	IL 1986-98007	19860812
	ZA 8606097	A	19880330	ZA 1986-6097	19860813
	CA 1308707	A1	19921013	CA 1986-516177	19860818
	AU 8663356	A1	19870407	AU 1986-63356	19860828
	AU 593284	B2	19900208		
	EP 238545	A1	19870930	EP 1986-905605	19860828
	EP 238545	B1	19951115		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 63500868	T2	19880331	JP 1986-504810	19860828
	JP 05035158	B4	19930525		
	AT 130307	E	19951215	AT 1986-905605	19860828
	CN 86106226	A	19870318	CN 1986-106226	19860912
	CN 1030319	B	19951122		
	DK 8702375	A	19870511	DK 1987-2375	19870511
	DK 175347	B1	20040906		
	NO 8701930	A	19870511	NO 1987-1930	19870511
	NO 176762	B	19950213		
	NO 176762	C	19950531		
	FI 8702107	A	19870512	FI 1987-2107	19870512
	FI 94417	B	19950531		
	FI 94417	C	19950911		
	US 5099019	A	19920324	US 1988-229675	19880808
	AU 8940806	A1	19891207	AU 1989-40806	19890825
	AU 614661	B2	19910905		
	AU 8940807	A1	19891207	AU 1989-40807	19890825
	AU 614418	B2	19910829		
	US 5175281	A	19921229	US 1991-749830	19910826
	US 5322943	A	19940621	US 1991-749829	19910826
	JP 05112597	A2	19930507	JP 1992-8428	19920121
	US 35053	E	19951010	US 1992-959310	19921009
	US 5268477	A	19931207	US 1992-977768	19921119
	US 5380839	A	19950110	US 1992-983082	19921201
	US 5380840	A	19950110	US 1992-983084	19921201
	US 5380841	A	19950110	US 1992-984299	19921201
	US 5382661	A	19950117	US 1992-984298	19921201
	US 5506354	A	19960409	US 1992-984302	19921201
PRAI	US 1985-775204	A	19850912		
	US 1985-811058	A	19851219		
	US 1986-877287	A	19860623		
	US 1986-888231	A	19860729		
	IL 1986-79702	A	19860812		
	WO 1986-US1797	A	19860828		
	US 1987-121822	B2	19870511		
	US 1988-227812	B2	19880803		
	US 1988-229675	A3	19880808		
	US 1991-749829	A3	19910826		
	US 1991-749830	A3	19910826		

IT **111669-14-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation of, with piperazine)
RN 111669-14-8 CAPLUS
CN Pyrimidine, 4-chloro-2,6-bis(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



IT **111640-52-9P 111691-73-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)
RN 111640-52-9 CAPLUS
CN Pregna-4,9(11)-diene-3,20-dione, 21-[4-[2,6-bis(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-17-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111691-73-7 CAPLUS
CN Pregna-4,9(11)-diene-3,20-dione, 21-[4-[2,6-bis(4-methyl-1-piperazinyl)-4-pyrimidinyl]-1-piperazinyl]-17-hydroxy-, methanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 111640-52-9
CMF C39 H58 N8 O3

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



IT **111641-14-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for steroidal drugs)
RN 111641-14-6 CAPLUS
CN Pyrimidine, 2,4-bis(4-methyl-1-piperazinyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:102312 CAPLUS
DN 106:102312
TI 2,4-Diaminopyrido[2,3-d]pyrimidines
IN Meyer, Horst; Wehinger, Egbert; Garthoff, Bernward; Kazda, Stanislav
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., 85 pp.

CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3501696	A1	19860724	DE 1985-3501696	19850119
	NO 8505342	A	19860721	NO 1985-5342	19851230
	NO 164353	B	19900618		
	NO 164353	C	19900926		
	EP 189045	A2	19860730	EP 1986-100096	19860107
	EP 189045	A3	19881005		
	EP 189045	B1	19900214		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	US 4621082	A	19861104	US 1986-816594	19860107
	AT 50407	E	19900215	AT 1986-100096	19860107
	AU 8652193	A1	19860724	AU 1986-52193	19860110
	AU 578783	B2	19881103		
	FI 8600197	A	19860720	FI 1986-197	19860116
	FI 81574	B	19900731		
	FI 81574	C	19901112		
	IL 77621	A1	19890131	IL 1986-77621	19860116
	DK 8600233	A	19860720	DK 1986-233	19860117
	JP 61167688	A2	19860729	JP 1986-6593	19860117
	ZA 8600363	A	19860924	ZA 1986-363	19860117
	HU 40127	A2	19861128	HU 1986-250	19860117
	HU 195812	B	19880728		
	ES 551013	A1	19870401	ES 1986-551013	19860117
	CA 1276636	A1	19901120	CA 1986-499768	19860117
	CN 86100279	A	19861119	CN 1986-100279	19860118
	CN 1010947	B	19901226		
PRAI	DE 1985-3501696	A	19850119		
	EP 1986-100096	A	19860107		

OS CASREACT 106:102312
IT **104990-34-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with methyleneacetoacetates)
RN 104990-34-3 CAPLUS
CN 4-Pyrimidinamine, 2,6-bis(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1979:121637 CAPLUS
DN 90:121637
TI Pyrimidine derivatives and their pharmaceutical use
IN Beguin, Alain
PA Societe Civile de Recherches et d'Applications Scientifiques, Fr.
SO Belg., 9 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 868539	A1	19781016	BE 1978-188906	19780628
	ZA 7803521	A	19790627	ZA 1978-3521	19780620
	FI 7801982	A	19790113	FI 1978-1982	19780621
	FI 63026	B	19821231		
	FI 63026	C	19830411		
	IN 148661	A	19810502	IN 1978-DE457	19780621
	AT 7804745	A	19800115	AT 1978-4745	19780629
	AT 358198	B	19800825		
	US 4174395	A	19791113	US 1978-921335	19780703
	NL 7807228	A	19790116	NL 1978-7228	19780704
	NL 170855	B	19820802		
	NL 170855	C	19830103		
	CH 632267	A	19820930	CH 1978-7417	19780707
	CA 1097645	A1	19810317	CA 1978-307056	19780710
	DK 7803106	A	19790113	DK 1978-3106	19780711
	DK 148685	B	19850902		
	DK 148685	C	19860217		
	SE 7807721	A	19790113	SE 1978-7721	19780711
	SE 436875	B	19850128		
	SE 436875	C	19850509		
	NO 7802408	A	19790115	NO 1978-2408	19780711
	NO 149846	B	19840326		
	NO 149846	C	19840704		
	ES 471608	A1	19790116	ES 1978-471608	19780711
	JP 54052088	A2	19790424	JP 1978-83620	19780711
	JP 57025554	B4	19820529		
	AU 7837934	A1	19800117	AU 1978-37934	19780711
	AU 517046	B2	19810702		
	DE 2830670	A1	19790118	DE 1978-2830670	19780712
	DE 2830670	C2	19830120		
	GB 2001069	A	19790124	GB 1978-29550	19780712
	GB 2001069	B2	19820120		
	FR 2397413	A1	19790209	FR 1978-20755	19780712
	FR 2397413	B1	19800718		
	FR 2400362	A1	19790316	FR 1978-20756	19780712
	FR 2400362	B1	19800606		
PRAI	GB 1977-29281	A	19770712		

IT **69570-87-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)

RN 69570-87-2 CAPLUS

CN 4H-1,3-Dioxino[4,5-c]pyridine, 5,5'-[(6-methyl-2,4-pyrimidinediyl)bis(4,1-piperazinediylmethylene)]bis[2,2,8-trimethyl- (9CI) (CA INDEX NAME)



IT **69570-85-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 69570-85-0 CAPLUS
CN 4-Pyridinemethanol, 3,3'-[(6-methyl-2,4-pyrimidinediyl)bis(4,1-piperazinediylmethylene)]bis[5-hydroxy-6-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1975:593382 CAPLUS
DN 83:193382
TI Piperazinopyrimidines
IN Louiseau, Gerard; Mattioda, Georges; Millischer, Rene; Obellianne, Pierre
PA Ugine Kuhlmann, Fr.
SO S. African, 23 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI ZA 7308542	A	19741030	ZA 1973-8542	19731106
PRAI ZA 1973-8542	A	19731106		

IT **55477-28-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and analgesic, antiserotonin, and spasmolytic activity of)
RN 55477-28-6 CAPLUS
CN Pyrimidine, 4-chloro-2,6-bis(4-methyl-1-piperazinyl)-5-(methylthio)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L4 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1975:471496 CAPLUS
DN 83:71496
TI Synthesis and pharmacological properties of 4-piperazino-5-methylthiopyrimidines. Selection of new antiemetic agents
AU Mattioda, Georges; Obellianne, Pierre; Gauthier, Henri; Loiseau, Gerard; Millischer, Rene; Donadieu, Anne M.; Mestre, Michel
CS Pharm. Div., Prod. Chim. Ugine Kuhlmann, Saint-Denis, Fr.
SO Journal of Medicinal Chemistry (1975), 18(6), 553-9
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 83:71496
IT **55921-69-2P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation and pharmacol. of)
RN 55921-69-2 CAPLUS
CN Pyrimidine, 4-chloro-2,6-bis(4-methyl-1-piperazinyl)-5-(methylthio)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1975:443369 CAPLUS
DN 83:43369
TI Pyrimidine derivatives
IN Narr, Berthold; Roch, Josef; Mueller, Erich; Haarmann, Walter
PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 121 pp. Addn. to Ger. Offen. 2,430,644.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2341925	A1	19750306	DE 1973-2341925	19730820
	AT 7406079	A	19770515	AT 1974-6079	19740724
	AT 340933	B	19780110		
	NO 7402712	A	19750221	NO 1974-2712	19740725
	NO 141163	B	19791015		
	CS 187420	P	19790131	CS 1974-5405	19740729
	RO 65649	P	19810830	RO 1974-79722	19740810
	US 3975384	A	19760817	US 1974-497459	19740814
	DD 116831	C	19751212	DD 1974-180558	19740816
	HU 170230	P	19770428	HU 1974-TO978	19740817
	BE 818990	A1	19750219	BE 1974-147737	19740819
	FI 7402436	A	19750221	FI 1974-2436	19740819
	SE 7410539	A	19750221	SE 1974-10539	19740819
	NL 7411047	A	19750224	NL 1974-11047	19740819
	DK 7404415	A	19750428	DK 1974-4415	19740819
	JP 50049288	A2	19750501	JP 1974-94899	19740819
	AU 7472490	A1	19760219	AU 1974-72490	19740819
	ZA 7405305	A	19760428	ZA 1974-5305	19740819
	ES 429366	A1	19761016	ES 1974-429366	19740819
	PL 93115	P	19770530	PL 1974-173567	19740819
	CA 1043789	A1	19781205	CA 1974-207278	19740819
	FR 2241305	A1	19750321	FR 1974-28597	19740820
	GB 1449100	A	19760908	GB 1974-36606	19740820
PRAI	DE 1973-2341925	A	19730820		
	DE 1974-2430644	A	19740626		

IT **56033-92-2P 56034-18-5P 56034-72-1P 56034-93-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 56033-92-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2,4-di-1-piperazinyl-6-(4-thiomorpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 56034-18-5 CAPLUS
CN 4-Pyrimidinecarbonitrile, 6-(4-formyl-1-piperazinyl)-2-(1-piperazinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 56034-72-1 CAPLUS
CN Thiomorpholine, 4-(5-nitro-2,6-di-1-piperazinyl-4-pyrimidinyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 56034-93-6 CAPLUS
CN Thiomorpholine, 4-(5-nitro-2,6-di-1-piperazinyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1975:156376 CAPLUS
DN 82:156376
TI Piperazinopyrimidine derivatives and their use as mediums
IN Loiseau, Gerard; Mattioda, Georges; Millischer, Rene; Obellianne, Pierre
PA Ugine Kuhlmann
SO Ger. Offen., 28 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2342880	A1	19750130	DE 1973-2342880	19730824

	FR 2257294	A1	19750808	FR 1973-24874	19730706
	NO 7303260	A	19750107	NO 1973-3260	19730816
	NO 137205	B	19771010		
	BE 803803	A1	19740220	BE 1973-134751	19730820
	CH 582171	A	19761130	CH 1973-12136	19730823
	JP 50025578	A2	19750318	JP 1973-100728	19730906
	JP 58049548	B4	19831105		
	NL 7312321	A	19750108	NL 1973-12321	19730907
	NL 179257	B	19860317		
	NL 179257	C	19860818		
	GB 1434544	A	19760505	GB 1973-42866	19730912
PRAI	FR 1973-24874	A	19730706		

IT **55477-28-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activity of)
RN 55477-28-6 CAPLUS
CN Pyrimidine, 4-chloro-2,6-bis(4-methyl-1-piperazinyl)-5-(methylthio)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1970:55401 CAPLUS
DN 72:55401
TI Syntheses of N-heterocyclic compounds. I. Syntheses of 2,4,5-trisubstituted pyrimidine derivatives
AU Yurugi, Shojiro; Tomimoto, Mitsumi; Fushimi, Tomiyoshi
CS Takeda Chem. Ind. Ltd., Osaka, Japan
SO Takeda Kenkyusho Nenpo (1969), 28, 1-11
CODEN: TDKNAF; ISSN: 0371-5973
DT Journal
LA Japanese
IT **25693-84-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 25693-84-9 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2,4-bis(4-benzyl-1-piperazinyl)-, ethyl ester, trihydrochloride (8CI) (CA INDEX NAME)



● 3 HCl

L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1964:82906 CAPLUS
DN 60:82906
OREF 60:14520c-f
TI Pyrimidine derivatives
PA Burroughs Wellcome & Co. (U.S.A.) Inc.; Wellcome Foundation Ltd.
SO 5 pp.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 951432		19640000	GB	

IT **96166-89-1**, Pyrimidine, 5-[(p-chlorophenyl)thio]-2,4-bis(4-methyl-1-piperazinyl)-
(preparation of)
RN 96166-89-1 CAPLUS
CN Pyrimidine, 5-[(p-chlorophenyl)thio]-2,4-bis(4-methyl-1-piperazinyl)- (6CI, 7CI) (CA INDEX NAME)



L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1961:144248 CAPLUS
DN 55:144248
OREF 55:27349g-i,27350a-i,27351a-f
TI 5-Arylthiopyrimidines. II. 2- and 4-Alkylamine and 4-amine derivatives
AU Roth, Barbara; Hitchings, George H.
CS Wellcome Research Labs., Tuckahoe, NY
SO Journal of Organic Chemistry (1961), 26, 2770-8
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA Unavailable
OS CASREACT 55:144248

IT **96166-89-1**, Pyrimidine, 5-(p-chlorophenylthio)-2,4-bis(4-methyl-1-piperazinyl)-
(preparation of)
RN 96166-89-1 CAPLUS
CN Pyrimidine, 5-[(p-chlorophenyl)thio]-2,4-bis(4-methyl-1-piperazinyl)-
(6CI, 7CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	102.15	264.12

STN INTERNATIONAL LOGOFF AT 14:20:11 ON 27 SEP 2005